![Eduardo Bruno Martins](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Eduardo Bruno Martins
Direttore Tecnico/Scientifico/R&S presso SAGIMET BIOSCIENCES INC.
Patrimonio netto: 306 329 $ in data 30/06/2024
Posizioni attive di Eduardo Bruno Martins
Società | Posizione | Inizio | Fine |
---|---|---|---|
SAGIMET BIOSCIENCES INC. | Direttore Tecnico/Scientifico/R&S | 01/02/2021 | - |
Storia della carriera di Eduardo Bruno Martins
Precedenti posizioni note di Eduardo Bruno Martins
Società | Posizione | Inizio | Fine |
---|---|---|---|
ALLERGAN, INC. | Corporate Officer/Principal | 01/08/2018 | 01/05/2020 |
SCICLONE PHARMACEUTICALS, INC. | Direttore Tecnico/Scientifico/R&S | 01/01/1997 | 01/01/2005 |
Federal University of Rio de Janeiro | Corporate Officer/Principal | 01/01/1995 | 01/01/1999 |
ABBVIE INC. | Corporate Officer/Principal | - | - |
Martins Bruno Consulting LLC | Fondatore | - | - |
Eiger BioPharmaceuticals, Inc. /Old/
![]() Eiger BioPharmaceuticals, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Eiger BioPharmaceuticals, Inc. provides pharmaceutical products. It operates as a biopharmaceutical company, which focuses on the discovery and development of new antiviral agents against novel targets in the treatment of hepatitis. The firm’s pipeline includes clinical stage assets and preclinical new chemical entities (NCEs) shown to possess antiviral activity against Hepatitis C, Hepatitis D, and a wide array of other viruses. It also conducts multiple clinical proofs of concept studies in multiple clinical sites in HCV and HDV patients. The company was founded by Jeffrey S. Glenn in 2008 and is headquartered in Palo Alto, CA. | Corporate Officer/Principal | 20/10/2015 | - |
INTERMUNE INC | Direttore Tecnico/Scientifico/R&S | - | - |
DYNAVAX TECHNOLOGIES CORPORATION | Corporate Officer/Principal | 01/03/2006 | - |
Formazione di Eduardo Bruno Martins
University of Oxford | Doctorate Degree |
Federal University of Rio de Janeiro | Doctorate Degree |
Statistiche
Distribuzione geografica
Stati Uniti | 9 |
Regno Unito | 2 |
Brasile | 2 |
Posizioni
Corporate Officer/Principal | 5 |
Chief Tech/Sci/R&D Officer | 3 |
Doctorate Degree | 2 |
Settori
Health Technology | 8 |
Consumer Services | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 3 |
---|---|
DYNAVAX TECHNOLOGIES CORPORATION | Health Technology |
ABBVIE INC. | Health Technology |
SAGIMET BIOSCIENCES INC. | Health Technology |
Aziende private | 5 |
---|---|
Allergan, Inc.
![]() Allergan, Inc. Pharmaceuticals: MajorHealth Technology Allergan, Inc. operated as a global healthcare company. It engaged in the development and commercialization of specialty pharmaceutical, medical device ,and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, obesity intervention, urological, and other specialty markets. The company was founded by Gavin S. Herbert Sr. in 1950 and headquartered in Irvine, CA. | Health Technology |
SciClone Pharmaceuticals LLC
![]() SciClone Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology SciClone Pharmaceuticals LLC was engaged in the development of therapeutic treatment for oncology, infectious diseases, and cardiovascular disorders. It was also offering ZADAXIN for the treatment of hepatitis B, hepatitis C, certain cancers, and used as immune system enhancer, and DC Bead which is used for the novel treatment of liver cancer. The company was founded in 1990 and was headquartered in San Mateo, CA. | Health Technology |
InterMune, Inc.
![]() InterMune, Inc. BiotechnologyHealth Technology InterMune, Inc. operates as a biotechnology company that researches, develops and commercializes therapies in pulmonology and orphan fibrotic diseases. It focuses on therapies for the treatment of idiopathic pulmonary fibrosis, a progressive and fatal lung disease. The firms research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases. The company was founded in 1998 and is headquartered in South San Francisco, CA. | Health Technology |
Eiger BioPharmaceuticals, Inc. /Old/
![]() Eiger BioPharmaceuticals, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Eiger BioPharmaceuticals, Inc. provides pharmaceutical products. It operates as a biopharmaceutical company, which focuses on the discovery and development of new antiviral agents against novel targets in the treatment of hepatitis. The firm’s pipeline includes clinical stage assets and preclinical new chemical entities (NCEs) shown to possess antiviral activity against Hepatitis C, Hepatitis D, and a wide array of other viruses. It also conducts multiple clinical proofs of concept studies in multiple clinical sites in HCV and HDV patients. The company was founded by Jeffrey S. Glenn in 2008 and is headquartered in Palo Alto, CA. | Health Technology |
Martins Bruno Consulting LLC |